Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Inclusion Criteria:

• Subject must have a documented diagnosis of ocular hypertension, open angle glaucoma (with or without pseudoexfoliation or pigment dispersion component).

• Subject has a mean baseline IOP following washout in at least 1 eye (the same eye) of

≥ 24mmHg at Hour 0 (T0) at Baseline Visit 1 and Baseline Visit 2 (Day 1)

• Subject has a mean baseline IOP following washout in at least 1 eye (the same eye) of:

≥ 22mmHg at (T0 + 4h) and (T0 + 8h) at Baseline Visit 1 (note: the same eye must meetthe IOP eligibility criteria at all 4 baseline assessments)

• Washout IOP must be ≤ 34mmHg in each eye at all time points at the Baseline Visit 1and Baseline Visit 2 (Day 1)

Exclusion Criteria:

• Subject with any form of glaucoma other than open angle glaucoma (with or without apigment dispersion or pseudoexfoliation component).

• Subject with mean baseline IOP >34 mmHg in either eye at any time point during theBaseline Visits 1 or 2 (Day 1).

• Subject with a BCVA worse than 0.6 logMAR (20/80 Snellen) in either eye as measuredusing an ETDRS chart.

• Subject with a known or suspected allergy and/or hypersensitivity to travoprost,timolol, fluorescein or to any component of the study products.